This HTML5 document contains 118 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n17http://linked.opendata.cz/resource/AHFS/
foafhttp://xmlns.com/foaf/0.1/
n13http://linked.opendata.cz/resource/mesh/concept/
n4http://linked.opendata.cz/resource/drugbank/company/
n24http://linked.opendata.cz/resource/drugbank/drug/DB00808/identifier/wikipedia/
n19http://linked.opendata.cz/resource/drugbank/drug/DB00808/identifier/pharmgkb/
n29http://linked.opendata.cz/resource/drugbank/dosage/
n25http://linked.opendata.cz/resource/drugbank/drug/DB00808/identifier/bindingdb/
n20http://linked.opendata.cz/resource/drugbank/drug/DB00808/identifier/pubchem-compound/
n15http://bio2rdf.org/drugbank:
n9http://linked.opendata.cz/resource/drugbank/drug/DB00808/identifier/pubchem-substance/
n21http://linked.opendata.cz/resource/drugbank/drug/DB00808/identifier/kegg-drug/
admshttp://www.w3.org/ns/adms#
n23http://linked.opendata.cz/resource/drugbank/drug/DB00808/identifier/drugbank/
n28http://www.rxlist.com/cgi/generic/
n11http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n5http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n12http://linked.opendata.cz/ontology/mesh/
n22http://linked.opendata.cz/resource/drugbank/drug/DB00808/identifier/national-drug-code-directory/
n3http://linked.opendata.cz/ontology/drugbank/
n18http://www.drugs.com/cdi/
n14http://linked.opendata.cz/resource/drugbank/property/
n7http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/
xsdhhttp://www.w3.org/2001/XMLSchema#
n26http://linked.opendata.cz/resource/drugbank/drug/DB00808/identifier/chemspider/
n27http://linked.opendata.cz/resource/atc/
n16http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00808
rdf:type
n3:Drug
n3:description
A benzamide-sulfonamide-indole. It is called a thiazide-like diuretic but structure is different enough (lacking the thiazo-ring) so it is not clear that the mechanism is comparable. [PubChem]
n3:dosage
n29:271B408C-363D-11E5-9242-09173F13E4C5 n29:271B408D-363D-11E5-9242-09173F13E4C5 n29:271B408E-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# Dong DL, Wang QH, Yue P, Jiao JD, Gu RM, Yang BF: Indapamide induces apoptosis of GH3 pituitary cells independently of its inhibition of voltage-dependent K+ currents. Eur J Pharmacol. 2006 Apr 24;536(1-2):78-84. Epub 2006 Mar 2. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16556441
n3:group
approved
n3:halfLife
14 hours (biphasic)
n3:indication
For the treatment of hypertension, alone or in combination with other antihypertensive drugs, as well as for the treatment of salt and fluid retention associated with congestive heart failure or edema from pregnancy (appropriate only in the management of edema of pathologic origin during pregnancy when clearly needed). Also used for the management of edema as a result of various causes.
n3:manufacturer
n4:271B407D-363D-11E5-9242-09173F13E4C5 n4:271B407E-363D-11E5-9242-09173F13E4C5 n4:271B407B-363D-11E5-9242-09173F13E4C5 n4:271B407C-363D-11E5-9242-09173F13E4C5 n4:271B4079-363D-11E5-9242-09173F13E4C5 n4:271B407A-363D-11E5-9242-09173F13E4C5 n4:271B4080-363D-11E5-9242-09173F13E4C5 n4:271B4078-363D-11E5-9242-09173F13E4C5 n4:271B407F-363D-11E5-9242-09173F13E4C5
owl:sameAs
n11:DB00808 n15:DB00808
dcterms:title
Indapamide
adms:identifier
n9:46508626 n19:PA449975 n20:3702 n21:D00345 n22:0339-6494-11 n23:DB00808 n24:Indapamide n25:25901 n26:3574
n3:mechanismOfAction
Indapamide blocks the slow component of delayed rectifier potassium current (IKs) without altering the rapid component (IKr) or the inward rectifier current. Specifically it blocks or antagonizes the action the proteins KCNQ1 and KCNE1. Indapamide is also thought to stimulate the synthesis of the vasodilatory hypotensive prostaglandin PGE2.
n3:packager
n4:271B4077-363D-11E5-9242-09173F13E4C5 n4:271B4069-363D-11E5-9242-09173F13E4C5 n4:271B405E-363D-11E5-9242-09173F13E4C5 n4:271B405F-363D-11E5-9242-09173F13E4C5 n4:271B4062-363D-11E5-9242-09173F13E4C5 n4:271B4063-363D-11E5-9242-09173F13E4C5 n4:271B4060-363D-11E5-9242-09173F13E4C5 n4:271B4061-363D-11E5-9242-09173F13E4C5 n4:271B4066-363D-11E5-9242-09173F13E4C5 n4:271B4067-363D-11E5-9242-09173F13E4C5 n4:271B4064-363D-11E5-9242-09173F13E4C5 n4:271B4065-363D-11E5-9242-09173F13E4C5 n4:271B406B-363D-11E5-9242-09173F13E4C5 n4:271B406C-363D-11E5-9242-09173F13E4C5 n4:271B4068-363D-11E5-9242-09173F13E4C5 n4:271B406A-363D-11E5-9242-09173F13E4C5 n4:271B4070-363D-11E5-9242-09173F13E4C5 n4:271B4071-363D-11E5-9242-09173F13E4C5 n4:271B4074-363D-11E5-9242-09173F13E4C5 n4:271B4075-363D-11E5-9242-09173F13E4C5 n4:271B4072-363D-11E5-9242-09173F13E4C5 n4:271B4073-363D-11E5-9242-09173F13E4C5 n4:271B4076-363D-11E5-9242-09173F13E4C5 n4:271B406F-363D-11E5-9242-09173F13E4C5 n4:271B406D-363D-11E5-9242-09173F13E4C5 n4:271B406E-363D-11E5-9242-09173F13E4C5
n3:routeOfElimination
Indapamide is an extensively metabolized drug, with only about 7% of the total dose administered, recovered in the urine as unchanged drug during the first 48 hours after administration.
n3:synonym
Metindamide Indapamida Indapamid Indapamidum Indapamide
n3:toxicity
Side effects include electrolyte imbalance (potassium or salt depletion due to too much fluid loss), nausea, stomach disorders, vomiting, weakness
n16:hasAHFSCode
n17:40-28-24
n3:foodInteraction
Take without regard to meals. Magnesium, potassium and zinc needs increased.
n3:proteinBinding
71-79%
n3:synthesisReference
Chunyi Yeh, Yi-Lung Wang, Ya-Sheng Yang, Ya-Ching Chang Chein, "Oral sustained-release pharmaceutical composition of indapamide, production and use thereof." U.S. Patent US20060182803, issued August 17, 2006.
n12:hasConcept
n13:M0011207
foaf:page
n7:loz1241.shtml n18:indapamide.html n28:indap.htm
n3:IUPAC-Name
n14:271B4093-363D-11E5-9242-09173F13E4C5
n3:InChI
n14:271B4099-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n14:271B4098-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n14:271B4095-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n14:271B4096-363D-11E5-9242-09173F13E4C5
n3:SMILES
n14:271B4097-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n14:271B40A9-363D-11E5-9242-09173F13E4C5 n14:271B4091-363D-11E5-9242-09173F13E4C5
n3:logP
n14:271B40AB-363D-11E5-9242-09173F13E4C5 n14:271B408F-363D-11E5-9242-09173F13E4C5 n14:271B4092-363D-11E5-9242-09173F13E4C5
n3:logS
n14:271B4090-363D-11E5-9242-09173F13E4C5
n3:pKa
n14:271B40AC-363D-11E5-9242-09173F13E4C5
n16:hasATCCode
n27:C03BA11
n3:H-Bond-Acceptor-Count
n14:271B409F-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n14:271B40A0-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n14:271B409A-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n14:271B409B-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n14:271B409D-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n14:271B409C-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n14:271B409E-363D-11E5-9242-09173F13E4C5
n3:absorption
Rapidly absorbed from gastrointestinal tract.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
26807-65-8
n3:category
n3:containedIn
n5:271B408A-363D-11E5-9242-09173F13E4C5 n5:271B4087-363D-11E5-9242-09173F13E4C5 n5:271B4088-363D-11E5-9242-09173F13E4C5 n5:271B408B-363D-11E5-9242-09173F13E4C5 n5:271B4081-363D-11E5-9242-09173F13E4C5 n5:271B4082-363D-11E5-9242-09173F13E4C5 n5:271B4085-363D-11E5-9242-09173F13E4C5 n5:271B4086-363D-11E5-9242-09173F13E4C5 n5:271B4083-363D-11E5-9242-09173F13E4C5 n5:271B4084-363D-11E5-9242-09173F13E4C5 n5:271B4089-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n14:271B40A5-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n14:271B40A7-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n14:271B40A8-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n14:271B40AA-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n14:271B40A4-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n14:271B40A3-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n14:271B40A6-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n14:271B4094-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n14:271B40A1-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n14:271B40A2-363D-11E5-9242-09173F13E4C5